Fig. 3 | European Journal of Nuclear Medicine and Molecular Imaging

Fig. 3

From: RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer

Fig. 3

Baseline, 3 months and 6 months. (A) 18F-FDG PET/CT. (B) 18FNa PET/CT. and (C) 99mTc-HMDP bone scintigraphy. The patient presented at baseline 4 bone target lesions. Total SULpeak and total TLG at baseline 18F FDG PET were 39.1 and 335.3, respectively. He was defined as PD for ∆SULpeak of + 33% at 3 and 6 months (∆TLG of + 51% and + 72%, respectively). Total SUVmax at baseline 18FNa PET/CT was 107.4. He was defined with SD with ∆SUVmax of − 21.5% and − 22% after 3 and 6 administrations of Radium-223, respectively. Disease was considered stable at bone scintigraphy both at 3 and 6 months

Back to article page